Analysis Oncopeptides AB (0RN4)
5/28/2024
Analysis of Oncopeptides AB (0RN4)
Oncopeptides AB is showing a consistent price of 2.9 across multiple days, with no significant changes in the price range. The RSI indicator is at 36.12, indicating a slightly oversold condition. The MACD indicator is negative, with a value of -0.28, suggesting a bearish trend. The Moving Average (MA) indicator is at 3.09, which is below the current price, indicating a potential downward movement.Overall, based on the indicators and the price stability, Oncopeptides AB seems to be in a consolidation phase with a bearish bias. Traders and investors may want to monitor the price action closely for any potential breakout or reversal signals before making any trading decisions.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a relatively low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with a high price-to-book ratio and price-to-sales ratio.
The stock price summary includes beta, moving averages, and the range of prices over the past year.
Lastly, dividends and splits data show the company's dividend history, payout ratio, and dividend yield metrics. The company has a regular dividend payment schedule and has undergone a stock split in the past.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, the gross profit has generally followed the trend of increasing sales revenue.
3. The company has been able to maintain a healthy EBITDA margin, with EBITDA reaching $129.2 billion in 2023.
4. Net income has also shown an increasing trend, reaching $97 billion in 2023 from $57.4 billion in 2020.
5. Earnings per share (EPS) have shown slight fluctuations but have generally increased over the years.
6. The company has effectively managed its operating expenses, with operating income showing a positive trend.
7. The company has been able to generate consistent income from its core operations, as indicated by the net income from continuous operations.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, from $323.9 billion in 2018 to $352.8 billion in 2023.
2. Current assets have fluctuated but generally increased, with a peak in 2019 at $162.8 billion and a slight decrease to $143.7 billion in 2020 before rising again.
3. Non-current assets have shown a consistent increase over the years, reaching $78.3 billion in 2023.
4. Total liabilities have also been on the rise, from $255.4 billion in 2018 to $290.4 billion in 2023.
5. Shareholders' equity has shown an increasing trend, with fluctuations, from $107.1 billion in 2018 to $62.1 billion in 2023.
6. The company has been investing more in non-current assets and has been able to maintain a healthy level of shareholders' equity despite increasing liabilities.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include acquisitions, capital expenditures, and the sale/purchase of investments.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, which is higher than the EPS of $1.26 from the same quarter a year ago. The range of estimates is between $1.27 and $1.36, as provided by 26 analysts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, compared to $1.46 from the previous year. The estimates range from $1.44 to $1.63, based on 25 analysts' forecasts.
3. Looking at the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, an increase from the previous year's EPS of $6.13. The analysts' estimates range from $6.43 to $6.92, with insights from 39 analysts.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $7.23, with a range of estimates between $6.40 and $7.90. This forecast is based on inputs from 39 analysts.
Overall, the analysts are predicting growth in earnings per share both for the upcoming quarters and the next fiscal years, indicating positive expectations for the company's performance.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company over the specified periods.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions about the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still projected to be positive.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price is $191.57, which is below the median and average forecast, indicating that some analysts may expect the price to increase in the future.
MACD of 0RN4
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
